Background: With no approved treatment for mild cognitive impairment
(MCI), attention increasingly turns to qualified food supplements.
Objective: To conduct a 12-month rater-blinded exploratory outpatient trial with Acutil®,
a supplement consisting of ω-3 polyunsaturated fatty acids, Ginkgo biloba extract, and
vitamins, in 50 persons with amnestic MCI or mild to moderate Alzheimer or mixed-type
Methods: The used cognitive tools were the Alzheimer's Disease Assessment Scale-
Cognitive Subscale (ADAS-Cog), the Mini-Mental State Exam (MMSE), and Controlled
Oral Word Association Test (COWAT). Patients were randomized in the ratio of 40:10 to
additional Acutil® or no additional supplementation; all continued on their existing medications
during the entire study.
Results: Only the COWAT produced a clear positive signal in the Acutil® group between
individual baseline and study endpoint, but the between-group comparison was not statistically
significant. The MMSE score remained stable in the Acutil® group while deteriorating
in the control group; post hoc examination suggests that the Acutil® group might
have contained responders. The ADAS-Cog and Clinical Dementia Rating (CDR) scores
showed marginal deterioration in both groups.
Conclusion: We tentatively interpret our results as potentially indicating positive effects of
Acutil® on verbal fluency and some aspects of executive function, with an onset after 6
months of continuous treatment. However, much larger and double-blinded studies will be
required to make firm statements.